Drupal.behaviors.print = function(context) {window.print();window.close();}>
Alnylam Data Shows 'Majority' of Patients in Liver Cancer Extension Study Have Stable Disease
June 07, 2012
Alnylam Data Shows 'Majority' of Patients in Liver Cancer Extension Study Have Stable Disease
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Alnylam Publishes Phase I Data on Liver Cancer Drug
January 31, 2013 / Gene Silencing News
Alnylam Adds New Program to Pipeline as It Shelves Anemia Candidate
January 10, 2013 / Gene Silencing News
Alnylam Licenses Chinese Rights to Liver Cancer Drug
July 12, 2012 / Gene Silencing News
Alnylam Steps Back from Huntington's Drug Deal, Sees Two Partnerships by Year-End
May 10, 2012 / Gene Silencing News
Alnylam Focuses on Two Lead Programs, Won't Advance Others without Partners
January 12, 2012 / Gene Silencing News